BioBrief covers a selective biotech session shaped by regulatory uncertainty, large-pharma pipeline sourcing, and concrete FDA filing progress.

In today’s BioBrief:

• FDA leadership — Leadership uncertainty at the agency became a market catalyst, lifting some FDA-sensitive biotech names while keeping regulatory predictability in focus.
• Bristol Myers Squibb / Hengrui Pharma — Bristol Myers announced a broad collaboration covering 13 programs across oncology, hematology, and immunology, with $600 million upfront and up to $15.2 billion in potential value.
• Kyverna / miv-cel — Kyverna began a rolling BLA submission for miv-cel in stiff person syndrome, potentially moving autoimmune CAR-T therapy closer to formal FDA review.
• Agios and BridgeBio — ...